---
document_datetime: 2025-11-23 11:41:32
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/zalmoxis.html
document_name: zalmoxis.html
version: success
processing_time: 0.0759917
conversion_datetime: 2025-12-24 07:30:14.9609
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Zalmoxis

[RSS](/en/individual-human-medicine.xml/66908)

##### Withdrawn

This medicine's authorisation has been withdrawn

allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Zalmoxis](#news-on)
- [More information on Zalmoxis](#more-information-on-zalmoxis-821)
- [More information on Zalmoxis](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 9 October 2019, the European Commission withdrew the marketing authorisation for Zalmoxis (nalotimagene carmaleucel) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, MolMed S.p.A, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Zalmoxis (nalotimagene carmaleucel) was granted marketing authorisation in the EU on 18 August 2016 as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies. This was a conditional marketing authorisation and was subsequently renewed yearly.

The European Public Assessment Report (EPAR) for Zalmoxis (nalotimagene carmaleucel) is updated to indicate that the marketing authorisation is no longer valid.

Zalmoxis : EPAR - Summary for the public

Reference Number: EMA/454627/2016

English (EN) (654.49 KB - PDF)

**First published:** 05/09/2016

**Last updated:** 05/09/2016

[View](/en/documents/overview/zalmoxis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-1)

български (BG) (760.89 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/bg/documents/overview/zalmoxis-epar-summary-public_bg.pdf)

español (ES) (653.89 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/es/documents/overview/zalmoxis-epar-summary-public_es.pdf)

čeština (CS) (733.96 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/cs/documents/overview/zalmoxis-epar-summary-public_cs.pdf)

dansk (DA) (653.11 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/da/documents/overview/zalmoxis-epar-summary-public_da.pdf)

Deutsch (DE) (655.77 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/de/documents/overview/zalmoxis-epar-summary-public_de.pdf)

eesti keel (ET) (650.21 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/et/documents/overview/zalmoxis-epar-summary-public_et.pdf)

ελληνικά (EL) (765.42 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/el/documents/overview/zalmoxis-epar-summary-public_el.pdf)

français (FR) (655.08 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fr/documents/overview/zalmoxis-epar-summary-public_fr.pdf)

hrvatski (HR) (664.62 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hr/documents/overview/zalmoxis-epar-summary-public_hr.pdf)

italiano (IT) (652.81 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/it/documents/overview/zalmoxis-epar-summary-public_it.pdf)

latviešu valoda (LV) (715.93 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lv/documents/overview/zalmoxis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (669.25 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lt/documents/overview/zalmoxis-epar-summary-public_lt.pdf)

magyar (HU) (727.73 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hu/documents/overview/zalmoxis-epar-summary-public_hu.pdf)

Malti (MT) (717.66 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/mt/documents/overview/zalmoxis-epar-summary-public_mt.pdf)

Nederlands (NL) (653.86 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/nl/documents/overview/zalmoxis-epar-summary-public_nl.pdf)

polski (PL) (733.21 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pl/documents/overview/zalmoxis-epar-summary-public_pl.pdf)

português (PT) (653.34 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pt/documents/overview/zalmoxis-epar-summary-public_pt.pdf)

română (RO) (668.59 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/ro/documents/overview/zalmoxis-epar-summary-public_ro.pdf)

slovenčina (SK) (732.91 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sk/documents/overview/zalmoxis-epar-summary-public_sk.pdf)

slovenščina (SL) (726.58 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sl/documents/overview/zalmoxis-epar-summary-public_sl.pdf)

Suomi (FI) (652.21 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fi/documents/overview/zalmoxis-epar-summary-public_fi.pdf)

svenska (SV) (651.83 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sv/documents/overview/zalmoxis-epar-summary-public_sv.pdf)

## Product information

Zalmoxis : EPAR - Product Information

English (EN) (1.09 MB - PDF)

**First published:** 05/09/2016

**Last updated:** 05/09/2016

[View](/en/documents/product-information/zalmoxis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-593)

български (BG) (1.71 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/bg/documents/product-information/zalmoxis-epar-product-information_bg.pdf)

español (ES) (1.04 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/es/documents/product-information/zalmoxis-epar-product-information_es.pdf)

čeština (CS) (1.62 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/cs/documents/product-information/zalmoxis-epar-product-information_cs.pdf)

dansk (DA) (856.94 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/da/documents/product-information/zalmoxis-epar-product-information_da.pdf)

Deutsch (DE) (939.53 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/de/documents/product-information/zalmoxis-epar-product-information_de.pdf)

eesti keel (ET) (1.05 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/et/documents/product-information/zalmoxis-epar-product-information_et.pdf)

ελληνικά (EL) (1.86 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/el/documents/product-information/zalmoxis-epar-product-information_el.pdf)

français (FR) (1.06 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fr/documents/product-information/zalmoxis-epar-product-information_fr.pdf)

hrvatski (HR) (1.19 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hr/documents/product-information/zalmoxis-epar-product-information_hr.pdf)

íslenska (IS) (1.03 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/is/documents/product-information/zalmoxis-epar-product-information_is.pdf)

italiano (IT) (1.09 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/it/documents/product-information/zalmoxis-epar-product-information_it.pdf)

latviešu valoda (LV) (1.64 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lv/documents/product-information/zalmoxis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.12 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lt/documents/product-information/zalmoxis-epar-product-information_lt.pdf)

magyar (HU) (1.62 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hu/documents/product-information/zalmoxis-epar-product-information_hu.pdf)

Malti (MT) (1.65 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/mt/documents/product-information/zalmoxis-epar-product-information_mt.pdf)

Nederlands (NL) (1004.44 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/nl/documents/product-information/zalmoxis-epar-product-information_nl.pdf)

norsk (NO) (1.08 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/no/documents/product-information/zalmoxis-epar-product-information_no.pdf)

polski (PL) (1.63 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pl/documents/product-information/zalmoxis-epar-product-information_pl.pdf)

português (PT) (1.04 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pt/documents/product-information/zalmoxis-epar-product-information_pt.pdf)

română (RO) (1.12 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/ro/documents/product-information/zalmoxis-epar-product-information_ro.pdf)

slovenčina (SK) (1.62 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sk/documents/product-information/zalmoxis-epar-product-information_sk.pdf)

slovenščina (SL) (1.64 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sl/documents/product-information/zalmoxis-epar-product-information_sl.pdf)

Suomi (FI) (1.16 MB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fi/documents/product-information/zalmoxis-epar-product-information_fi.pdf)

svenska (SV) (913.58 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sv/documents/product-information/zalmoxis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0009/G 26/07/2018

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Zalmoxis : EPAR - All Authorised presentations

English (EN) (577.05 KB - PDF)

**First published:** 05/09/2016

**Last updated:** 05/09/2016

[View](/en/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-934)

български (BG) (620.06 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/bg/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_bg.pdf)

español (ES) (577.71 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/es/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (608.26 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/cs/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (577.54 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/da/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (577.51 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/de/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (577.67 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/et/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (619.96 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/el/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_el.pdf)

français (FR) (577.52 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fr/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (591.71 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hr/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (577.59 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/is/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (577.7 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/it/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (610.12 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lv/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (594.87 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/lt/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (599.51 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/hu/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (611.06 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/mt/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (577.31 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/nl/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (577.68 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/no/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_no.pdf)

polski (PL) (609.04 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pl/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_pl.pdf)

português (PT) (577.7 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/pt/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_pt.pdf)

română (RO) (592.97 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/ro/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (600.14 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sk/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (605.32 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sl/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (577.43 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/fi/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (577.6 KB - PDF)

**First published:**

05/09/2016

**Last updated:**

05/09/2016

[View](/sv/documents/all-authorised-presentations/zalmoxis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Zalmoxis Active substance allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) International non-proprietary name (INN) or common name allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2) Therapeutic area (MeSH)

- Hematopoietic Stem Cell Transplantation
- Graft vs Host Disease

Anatomical therapeutic chemical (ATC) code L01

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Zalmoxis is indicated as adjunctive treatment in haploidentical haematopoietic stem cell transplantation (HSCT) of adult patients with high-risk haematological malignancies.

## Authorisation details

EMA product number EMEA/H/C/002801

Advanced therapy

This medicine is classified as an advanced therapy medicinal product (ATMP): a medicine for human use that is based on genes, tissues or cells. It offers groundbreaking new opportunities for the treatment of disease and injury. For more information, see [Advanced therapy medicinal products: Overview](/node/69659) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Marketing authorisation holder

MolMed SpA

Via Olgettina 58

Opinion adopted 23/06/2016 Marketing authorisation issued 18/08/2016 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Zalmoxis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (650.45 KB - PDF)

**First published:** 31/08/2018

**Last updated:** 31/08/2018

[View](/en/documents/procedural-steps-after/zalmoxis-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Zalmoxis : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/589978/2016

English (EN) (3.12 MB - PDF)

**First published:** 05/09/2016

**Last updated:** 05/09/2016

[View](/en/documents/assessment-report/zalmoxis-epar-public-assessment-report_en.pdf)

CHMP summary of opinion for Zalmoxis

Adopted

Reference Number: EMA/CHMP/380467/2016

English (EN) (677.27 KB - PDF)

**First published:** 24/06/2016

**Last updated:** 24/06/2016

[View](/en/documents/smop-initial/chmp-summary-opinion-zalmoxis_en.pdf)

#### News on Zalmoxis

[New cell-based therapy to support stem cell transplantation in patients with high-risk blood cancer](/en/news/new-cell-based-therapy-support-stem-cell-transplantation-patients-high-risk-blood-cancer) 24/06/2016

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2016](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-20-23-june-2016) 24/06/2016

#### More information on Zalmoxis

This product was originally [designated an orphan medicine](/en/medicines/human/orphan-designations/eu-3-03-168) on 20 October 2003. Zalmoxis was withdrawn from the Community register of orphan medicinal products by the European Commission in October 2019 at the time of the withdrawal of the marketing authorisation.

#### More information on Zalmoxis

- [TK011: Prospective, non-interventional, post-authorisation safety study (PASS) of Zalmoxis prescribed in patients undergoing haploidentical hematopoietic stem cell transplantation for high-risk hematological malignancies - post-authorisation study](https://catalogues.ema.europa.eu/study/46455)

**This page was last updated on** 14/02/2020

## Share this page

[Back to top](#main-content)